Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-23-000174

← back to feed
Filed
Jan 13, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Jan 14, 2023 1.26M sh
Cash And Equivalents Q1 2023 · Nov 30, 2022 $21.6K
Cash And Equivalents Q1 2023 · Aug 31, 2022 $117.52K
Current Liabilities Q1 2023 · Nov 30, 2022 $2.58M
Current Liabilities Q1 2023 · Aug 31, 2022 $2.44M
Current Assets Q1 2023 · Nov 30, 2022 $99.69K
Current Assets Q1 2023 · Aug 31, 2022 $198.29K
Total Assets Q1 2023 · Nov 30, 2022 $609.51K
Total Assets Q1 2023 · Aug 31, 2022 $811.17K
Shares Diluted Q1 2023 · Nov 30, 2021 131.11M sh
Operating Cash Flow Q1 2023 · Nov 30, 2021 −$599.55K
Stockholders Equity Q1 2023 · Nov 30, 2021 $627.42K
Stockholders Equity restated Q1 2023 · Aug 31, 2021 $1.81M
Eps Diluted Q1 2023 · Nov 30, 2021 −$0.01
Eps Basic Q1 2023 · Nov 30, 2021 −$0.01
Sga Expense restated Q1 2023 · Nov 30, 2021 $670.31K
Rd Expense Q1 2023 · Nov 30, 2021 $440.04K
Net Income Q1 2023 · Nov 30, 2021 −$1.32M
Operating Income Q1 2023 · Nov 30, 2021 −$1.11M